Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-20-018491

Options or other derivatives

  • Executive VP, Head of R&D acquired 68,750 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Ho Tony W Executive VP, Head of R&D 2020-03-10 Grant or award · Stock Option (Right to Buy) +55,000 55,000 D
Ho Tony W Executive VP, Head of R&D 2020-03-10 Grant or award · Restricted Stock Units +13,750 13,750 D
Loading xslF345X03/doc4.xml…